GAS5 and breast cancer: Not all treatments show dependence on GAS5 lncRNA for their action, insofar as imatinib-induced death of breast cancer cells is unaffected by GAS5 silencing [49], however the action of another tyrosine kinase inhibitor, gefitinib, shows GAS5-dependence in lung cancer cells [34].